RudaCure (CEO Yongho Kim), a company specializing in 感觉障碍 treatment development, announced on the 21st that it has been selected for the 中小企业部' 'Scale-up TIPS' program, recognized for its 非麻醉性镇痛药 development capabilities through 离子通道 modulation.
'Scale-up TIPS' is a government private investment-led 研发 support program that enables promising technology-based SMEs and ventures to boldly pursue high-risk, innovative 研发. When a private operator invests KRW 1 billion or more, the government provides up to KRW 2 billion for investment-type 研发 and up to KRW 1.2 billion over 3 years for investment-linked 研发.
Through this program, RudaCure plans to receive a total of KRW 1.2 billion in support over the next 3 years to accelerate the commercialization of its 非麻醉性镇痛药 RCI002 project.
The compound discovered by RudaCure simultaneously acts on both the 离子通道 TRPV1 and MOR (Mu阿片受体). This is a differentiated 非麻醉性镇痛药 approach that overcomes the 成瘾性 and 耐药性 issues of existing MOR-targeting 麻醉性镇痛药 while addressing the 体温升高 副作用 associated with TRPV1 channel modulation.
RudaCure stated, "Through this Scale-up TIPS selection, we have established a foundation for accelerating the commercialization of the RCI002 project. We will do our best to lead the next-generation 非麻醉性镇痛药 market based on our 离子通道 modulation technology."